The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
Sign Up to like & getrecommendations! Published in 2020 at "Neuropsychopharmacology"
DOI: 10.1038/s41386-020-0764-2
Abstract: The group 2 metabotropic glutamate receptor (mGluR2/3) agonist, pomaglumetad methionil (POM), showed promise as a novel antipsychotic in preclinical research but failed to show efficacy in clinical trials, though it has been suggested that it… read more here.
Keywords: mglur2 agonist; neuron activity; mam rats; pom ... See more keywords